DUBLIN – Almost 12 months after its initial cash raise, Immunic AG finally closed out its series A round with an additional €10 million (US$11.9 million), taking the grand total to €31.7 million.
DUBLIN – Astrazeneca could garner as much as $400 million from a deal with Takeda Pharmaceutical Co. Ltd. to co-develop its preclinical alpha-synuclein-targeting antibody, MEDI-1341, which is slated to enter clinical development in Parkinson's disease before year-end.
DUBLIN – Astrazeneca could garner as much as $400 million from a deal with Takeda Pharmaceutical Co. Ltd. to co-develop its preclinical alpha-synuclein-targeting antibody, MEDI-1341, which is slated to enter clinical development in Parkinson's disease before year-end. The headline value of the alliance covers an up-front payment as well as development and sales milestones.
DUBLIN – The numbers for the Cantos phase III cardiovascular outcomes trial of Novartis AG’s interleukin-beta1 (IL-beta1) inhibitor, canakinumab, are in.
DUBLIN – A certain DNA endonuclease from Streptococcus pyogenes, Cas9, has gained enormous prominence as part of the revolutionary CRISPR-Cas9 genome editing system, but Hansa Medical AB is making waves with a different enzyme from the same bug, an endopeptidase that chews up immunoglobulin G (IgG) antibodies and which could reduce the risk of kidney transplant rejection in high-risk patients.
DUBLIN – Bavarian Nordic A/S has landed another vaccine development deal with Johnson & Johnson, an alliance worth up to $879 million covering the use of its modified vaccinia ankara (MVA-BN) technology in the development of vaccines against HIV-1 and hepatitis B virus (HBV). Kvistgaard, Denmark-based Bavarian Nordic is receiving $10 million of the total as an up-front payment and another $33 million as an equity investment.
DUBLIN – Antibiotics developer Venatorx Pharmaceuticals Inc. raised $42 million in a series B round that will fund a registration trial of its lead program, VNRX-5133, which it has penciled in for the first half of next year.
DUBLIN – Ablynx NV entered a broadly based alliance with Sanofi SA focused on the development of up to eight multispecific nanobodies across a range of immune-mediated conditions, in return for which it is getting €23 million (US$26.5 million) up front, €8 million in research funding and up to €2.4 billion in milestone payments. It also stands to earn tiered royalties on eventual product sales.
DUBLIN – Horama SA, an early stage French gene therapy firm, is waiting for regulatory feedback on its first clinical trial authorization (CTA) before moving into clinical development.
